Showing results (41-50 of 427) with videos related to

Sort By:
Pageof 43
Research and Practice in Thrombosis and Haemostasis|December 16, 2024
Utilizing artificial intelligence for the detection of hemarthrosis in hemophilia using point-of-care ultrasonographyPascal N Tyrrell, María Teresa Alvarez-Román, Nihal Bakeer, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Solution biophysics identifies lipid nanoparticle non-sphericity, polydispersity, and dependence on internal ordering for efficacious mRNA deliveryMarshall S Padilla, Sarah J Shepherd, Andrew R Hanna, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 2026
Plug-and-play assembly of biodegradable ionizable lipids for potent mRNA delivery and gene editing in vivoXuexiang Han, Ying Xu, Adele S Ricciardi, et al.
Nature Biotechnology|October 23, 2025
Elucidating lipid nanoparticle properties and structure through biophysical analysesMarshall S Padilla, Sarah J Shepherd, Andrew R Hanna, et al.
Molecular Therapy. Nucleic Acids|May 18, 2023
<i>In utero</i> delivery of miRNA induces epigenetic alterations and corrects pulmonary pathology in congenital diaphragmatic herniaSarah J Ullrich, Nicholas K Yung, Tory J Bauer-Pisani, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Automated and parallelized microfluidic generation of large and precisely-defined lipid nanoparticle librariesAndrew R Hanna, Sarah J Shepherd, Gregory A Datto, et al.
Haematologica|May 1, 1996
Multiple myeloma in the elderly: clinical features and response to treatment in 113 patientsM Clavio, S Casciaro, A M Gatti, et al.
Acta Biomaterialia|January 23, 2021
Nanoparticles for delivery of agents to fetal lungsSarah J Ullrich, Mollie Freedman-Weiss, Samantha Ahle, et al.
Science Advances|October 5, 2022
In vivo correction of cystic fibrosis mediated by PNA nanoparticlesAlexandra S Piotrowski-Daspit, Christina Barone, Chun-Yu Lin, et al.
ACS Nano|April 4, 2025
Lipid Nanoparticles for <i>In Vivo</i> Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical TargetsRebecca M Haley, Marshall S Padilla, Rakan D El-Mayta, et al.
Pageof 43